Eisai Joins Up With Valeant To Promote Halaven

After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant’s PharmaSwiss division will distribute Halaven (eribulin) in Bulgaria, Romania, Latvia,

Continue Reading

UK MPs Approve Controversial NHS Bill

The NHS health bill has survived the final parliamentary test and is set to become law. Labour’s call for MPs to delay their final consideration of the NHS overhaul in England until an evaluation of the potential risks is available was defeated by 82 votes. An emergency debate over the proposed Health and Social Care

Continue Reading

Pharmaceutical Industry Should Invest Further in Anti-Obesity Drugs

Pharmaceutical organisations should increase their investment in anti-obesity drugs to respond to the rising number of clinically obese people globally. This is the main message from a report by business intelligence specialist, GlobalData, which observes that the obesity market is lucrative, largely driven by the embracement of sedentary lifestyles, high cholesterol diets and reduced physical

Continue Reading

ICON’s MIRA Chosen by Roche for Medical Image Repository

Continuing its move from transactional relationships to strategic alliances with clients, ICON have announced that they have been chosen by Roche as Roche’s technology partner for storing and managing medical images collected during clinical research programmes. ICON is an international supplier of outsourced development services to the pharmaceutical, biotechnology and medical device industries.  The Company

Continue Reading